Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

Antibe Therapeutics Inc(Pre-Merger) > Expensive Pfizer drug for OA likely to fail
View:
Comment by Straylight on Mar 25, 2021 12:15pm
Nice article. Couple good quotes about that drug from the link: "Although FDA said tanezumab proved to be effective, its effect size “is modest, and there is no convincing evidence of a superior efficacy of tanezumab over NSAIDs.” "In addition, the agency said tanezumab is associated with an elevated risk of requiring a total joint replacement, as observed in two of the three post-2015 ...more  
Comment by bringon10bagger on Mar 25, 2021 1:24pm
That's welcoming to understand the FDA and their positioning for improvement in treatment over existing NSAID, and knowing the qualities of  ATB-346 over existing NSAID things look very encouraging....SUPER GI Safe over existing, smaller dosing for better WOMAC results  and could be less than already established and notthing else any worse than existing NSAID's. THAT'S ...more  
Comment by Actuarial on Mar 25, 2021 1:42pm
Only one member voted yes and he/she is one of the two consumer reps. What a failure! "Outside experts advising the FDA voted 19 to 1 against (one of the two consumer reps voted yes) Pfizer’s potential osteoarthritis drug tanezumab, saying the proposed risk evaluation and mitigation strategy (REMS) will not ensure the benefits of the drug outweigh the risks."
Comment by YukonJezza on Mar 25, 2021 1:47pm
would be smart for Pfizer to scraptanezumab. The should BuY ATE out .
Comment by Straylight on Mar 25, 2021 1:58pm
Reading that article I was thinking the same thing. 
Comment by markymark11 on Mar 25, 2021 2:39pm
It would be nice if Dan released a statement on the back of this FDA/Tanezumab news to reiterate Otenaproxesul's potential as a best-in-class NSAID for OA pain.
Comment by Marky1 on Mar 25, 2021 3:00pm
MarkyMark....why don't you write him and tell him your thoughts! Dan is great on answering letters...I forwarded that article to him...if he responds I shall put It on here...We need some catalyst to get our SP to a value that is realistic...been a long long voyage, but our day will be coming very soon...There I are just  too many positives available. ...Come on Dan...I believe! 
Comment by Notthatbright on Mar 25, 2021 3:14pm
Dan is goverened by the BOD.  He alone cannot represent himself or the Company.  We, as much as we hate to wait, must wait. IMO
Comment by endpntplay on Mar 25, 2021 3:16pm
I think the best way forward is to include the FDAs own comments on an expensive drug like this in their own FDA filings to support approval for Otena. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities